




Supplemental Figure 1:

Time courses of Dvl1, Dvl2 and Dvl3 mRNA expression in (A) Dact1SH and (B) Dact1 over-expressing cells during adipogenic treatment. Experimental treatment and analyses were as described in legend for Figure 4.




A

● CtrlSH
○ Dact1SH



B

■ EV
□ Dact1



Supplemental Figure 2:

TZD feeding or treatment regulates *Dact1*, *Wnt10b* primarily in preadipocytes and in Stromavascular WAT fractions.

Dact1, *Wnt10b*, *Sfrp5* mRNA levels were measured in 3T3-L1 preadipocytes, in vitro differentiated 3T3-L1 adipocytes and in white adipose tissue fractions; stromavascular (SVF) and mature adipocytes (MA) after indicated treatments. Data are normalised to 18s mRNA. **(A-D)** Expression data from invitro cultured 3T3-L1 preadipocytes (day 0) and adipocytes (day 8 post differentiation). Data are from three independent experiments. Both cell types were treated to 1 μ M or 10 μ M rosiglitazone for 24 hrs prior to RNA extraction. **(E-H)** Expression data from 11 week-old C57/B6 mice fed rodent chow supplemented with or without rosiglitazone (TZD) for three weeks (n=10 per group). *P<0.05, **P<0.01, ***P<0.001 versus untreated controls.

